false
0001500198
0001500198
2023-12-14
2023-12-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 14, 2023
NeuroOne Medical Technologies Corporation
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40439 |
|
27-0863354 |
(State or other
jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
7599 Anagram Dr., Eden Prairie, MN 55344
(Address of principal executive offices and zip
code)
952-426-1383
(Registrant’s telephone number including
area code)
(Registrant’s former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
NMTC |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On December 14, 2023, NeuroOne Medical Technologies
Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year
ended September 30, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
In accordance with General Instruction B.2. of
Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that
section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended,
or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as
expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NEUROONE MEDICAL TECHNOLOGIES CORPORATION |
Dated: December 14, 2023 |
|
|
|
By: |
/s/ David Rosa |
|
|
David Rosa |
|
|
Chief Executive Officer |
2
Exhibit 99.1
NeuroOne®
Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn.,
December 14, 2023 (GlobeNewswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the
“Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from
neurological disorders, today announces its operating results for the fiscal fourth quarter and full fiscal year ended September 30, 2023.
Fiscal Fourth Quarter
2023 and Recent Business Updates
Financial Highlights:
| ● | Product revenue of $742,000 in Q4 2023,
compared to $69,000 in Q4 2022 |
| ● | Product revenue of $1,952,000 for FY 2023, compared
to $171,000 for FY 2022 |
| ● | Completed capital raise of $6M in July
2023 with net proceeds of $5.2M and raised an additional $2.5M using the ATM program at an average price of $1.77 per
share |
Evo® sEEG:
| ● | Zimmer Biomet expanded the launch to new centers
as the sites receive internal approval to evaluate the Evo electrode product line |
| ● | Collected
feedback remains positive |
| ● | Device sales and revenue ramp expected to continue
quarter by quarter |
| ● | Completed additional sales training for Zimmer
Biomet personnel |
OneRF™
Ablation System:
| ● | Received feedback from FDA on 510(k) submission
in August 2023 and the Company responded to FDA questions in November 2023 |
| ● | Received FDA clearance for OneRF Ablation
System in December 2023 |
| ● | Placed component orders for OneRF Ablation System
for commercialization |
| ● | Presented poster on pre-clinical experience with
the OneRF Ablation System at the Congress of Neurological Surgeons (CNS) Meeting in September 2023 |
Spinal Cord Stimulation
Program:
| ● | Completed test of an implantable pulse generator
(IPG) to test electrode fluid ingress |
| ● | Successfully performed percutaneous placement
of a 9mm paddle electrode in a human cadaver model with our physician advisory board |
| ● | Completed histological analysis of a 28-day implanted
Company electrode |
Drug Delivery Program:
| ● | Defined product requirements for drug delivery
system for both clinical and research use in the biotech and pharma industry |
| ● | Developed prototypes for future pre-clinical
studies |
| ● | Initiated licensing discussion with gene therapy
company for use in clinical studies |
| ● | Received patent for drug delivery system |
Dave Rosa, CEO of NeuroOne, commented,
“During and subsequent to our fiscal fourth quarter, the Company continued to execute at a high level on our strategic plan.
We were proud to announce the FDA clearance of our OneRF Ablation System, the Company’s first device that has an indication
for both recording electrical activity as well as ablation of nervous tissue and the first device with an FDA clearance. We believe
this device has the capability to create a paradigm shift in neurosurgical procedures. We expect to commercially launch this product
either directly or with a strategic partner in the first half of 2024. This represents the third FDA clearance in the
Company’s history and a monumental achievement. In addition, Zimmer Biomet continues to expand the commercial launch of our
Evo sEEG electrode as centers receive approval from their respective product committees to trial the technology. We also continue to
be bullish on the opportunity to deliver drugs or gene therapies and record the impact of these therapies using our sEEG electrode.
We have already held discussions with a Company that has strong interest in using our electrode in their clinical trial to evaluate
the performance of their therapy. The Company has made great strides in all areas, and I look forward to continuing to lead the
Company as we execute our strategic plan.”
Upcoming Targeted Milestones
Evo sEEG:
| ● | Complete full sales force training in early 2024 |
| ● | Continued product roll-out to additional US centers |
OneRF Ablation System:
| ● | Develop commercialization plan for product launch |
| ● | Place stocking orders for system components |
| ● | Present at the Society of Neuroscience and American
Epilepsy Society meetings |
SCS Program:
| ● | Complete animal protocol to evaluate stimulation
and battery performance using the Company’s spinal cord stimulation electrode technology |
Drug Delivery Program:
| ● | Continue to gather product requirements for drug
delivery system for both clinical and research use in the biotech and pharma industry |
| ● | Conduct large animal feasibility studies with
drug delivery system into the brain |
| ● | Advance contract discussions with gene therapy
company |
| ● | Investigate US regulatory pathway for device
clearance |
Fourth Quarter and
Full Fiscal Year 2023 Financial Results
Product revenue was $742,000 in
the fourth quarter of fiscal 2023 and $1,952,000 for the full fiscal year, compared to product revenue of $69,000 in the fourth quarter
and $171,000 for the full year of fiscal 2022. The Company had no collaboration revenue in the fourth quarter of fiscal 2023 and $1,455,000
for the full year of fiscal 2023, compared to collaboration revenue of $1,942,000 in the fourth quarter and $1,949,000 for the full year
of fiscal 2022. Collaboration revenue was derived from the Zimmer Development Agreement and represents the portion of the exclusivity
and milestone fee payments eligible for revenue recognition during the respective periods.
Total operating expenses
in the fourth quarter of fiscal 2023 were $3.4 million, compared with $3.3 million in the same period of the prior year.
R&D expense in the fourth quarter of fiscal 2023 was $1.8 million compared with $1.4 million in the same period
of fiscal 2022. SG&A expense in the fourth quarter of fiscal 2023 was $1.6 million compared with $1.9 million in
the same period of the prior year.
Total operating expenses
for the full fiscal year 2023 were $13.9 million, compared with $11.9 million in the prior fiscal year. R&D expense
for the full fiscal year 2023 was $6.9 million compared with $4.9 million in fiscal 2022. SG&A expense for the
full fiscal year 2023 was $6.9 million compared with $7.0 million in the same period of the prior year.
Net loss
was $3.1 million for the fourth quarter of fiscal 2023, compared to a net loss of $1.4 million in the same
period of the prior year. Net loss was $11.9 million for the full year fiscal 2023, compared to a net loss
of $10.0 million in fiscal 2022.
On July 27, 2023, the
Company completed an underwritten public offering of its common stock from which the Company received $5.2 million in net proceeds. In
addition, the Company sold common stock under the ATM program at an average price of $1.77 per share, from which the Company received
net proceeds of $2.5 million.
As of September
30, 2023, the Company had cash, cash equivalents, and short-term investments of $5.3 million, compared to $11.1 million as
of September 30, 2022. The Company had working capital of $5.5 million as of September 30, 2023, compared to working capital of $9.1
million as of September 30, 2022.
The Company had no debt
outstanding as of September 30, 2023.
About NeuroOne
NeuroOne Medical Technologies Corporation is a
developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation
and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company
may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial
intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release
may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this
press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are
subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking
statements. In some cases, you can identify forward–looking statements by the words or phrases “may,”
“might,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “objective,” “anticipate,” “believe,”
“estimate,” “predict,” “project,” “potential,” “target,”
“seek,” “contemplate,” “continue, “focused on,” “committed to” and
“ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the
future. Forward–looking statements may include statements regarding the development of the Company’s electrode
technology program, applications for, or receipt of, regulatory clearance, the timing and extent of product launch and
commercialization of our technology, receipt of revenues from sale of the sEEG electrodes, timing and success of any clinical and
pre-clinical testing, the timing and extent of product launch and commercialization of our OneRF Ablation System, the potential
capabilities of our OneRF Ablation System, SCS and drug delivery programs, business strategy, market size, potential growth opportunities,
future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a
reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely outside our control, including risks that the partnership with
Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain
disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on
results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital
requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or
retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology;
risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately
estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the
results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and
assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no
obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the
future.
Caution: Federal law
restricts this device to sale by or on the order of a physician.
Contact:
800-631-4030
ir@nmtc1.com
NeuroOne Medical Technologies Corporation
Balance Sheets
(unaudited)
| |
As of September 30, | |
| |
2023 | | |
2022 | |
Assets | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 5,322,493 | | |
$ | 8,160,329 | |
Short-term investments | |
| — | | |
| 2,981,010 | |
Accounts receivable | |
| — | | |
| 33,237 | |
Inventory | |
| 1,726,686 | | |
| 704,538 | |
Prepaid expenses | |
| 263,746 | | |
| 296,649 | |
Total current assets | |
| 7,312,925 | | |
| 12,175,763 | |
Intangible assets, net | |
| 89,577 | | |
| 111,892 | |
Right-of-use asset | |
| 169,059 | | |
| 181,355 | |
Property and equipment, net | |
| 525,753 | | |
| 353,599 | |
Total assets | |
$ | 8,097,314 | | |
$ | 12,822,609 | |
| |
| | | |
| | |
Liabilities and Stockholders’ Equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 685,104 | | |
$ | 927,662 | |
Accrued expenses and other liabilities | |
| 1,107,522 | | |
| 715,839 | |
Deferred revenue | |
| — | | |
| 1,455,188 | |
Total current liabilities | |
| 1,792,626 | | |
| 3,098,689 | |
Operating lease liability, long term | |
| 55,284 | | |
| 119,556 | |
Total liabilities | |
| 1,847,910 | | |
| 3,218,245 | |
| |
| | | |
| | |
Commitments and contingencies (Note 4) | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2023 and 2022; no shares issued or outstanding as of September 30, 2023 and 2022. | |
| — | | |
| — | |
Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2023 and 2022; 23,928,945 and 16,216,540 shares issued and outstanding as of September 30, 2023 and 2022, respectively. | |
| 23,929 | | |
| 16,217 | |
Additional paid–in capital | |
| 68,911,778 | | |
| 60,414,959 | |
Accumulated deficit | |
| (62,686,303 | ) | |
| (50,826,812 | ) |
Total stockholders’ equity | |
| 6,249,404 | | |
| 9,604,364 | |
Total liabilities and stockholders’ equity | |
$ | 8,097,314 | | |
$ | 12,822,609 | |
NeuroOne Medical Technologies Corporation
Statements of Operations
(unaudited)
| |
Years ended September 30, | |
| |
2023 | | |
2022 | |
Product revenue | |
$ | 1,952,441 | | |
$ | 171,169 | |
Cost of product revenue | |
| 1,495,924 | | |
| 241,963 | |
Product gross profit (loss) | |
| 456,517 | | |
| (70,794 | ) |
Collaboration revenue | |
| 1,455,188 | | |
| 1,948,872 | |
Operating expenses: | |
| | | |
| | |
Selling, general and administrative | |
| 6,926,269 | | |
| 6,979,416 | |
Research and development | |
| 6,940,686 | | |
| 4,929,427 | |
Total operating expenses | |
| 13,866,955 | | |
| 11,908,843 | |
Loss from operations | |
| (11,955,250 | ) | |
| (10,030,765 | ) |
Other income, net | |
| 95,759 | | |
| 31,152 | |
Net loss | |
$ | (11,859,491 | ) | |
$ | (9,999,613 | ) |
Net loss per share: | |
| | | |
| | |
Basic and diluted | |
$ | (0.65 | ) | |
$ | (0.63 | ) |
Number of shares used in per share calculations: | |
| | | |
| | |
Basic and diluted | |
| 18,121,108 | | |
| 15,998,567 | |
6
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfica de Acción Histórica
De May 2023 a May 2024